Organization | Emergent BioSolutions

Emergent BioSolutions Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4

Founded: Rockville MD United States (1998)

Organization Overview

First Clinical Trial

2002

NCT00042406

First Marketed Drug

1998

typhoid vaccine, live oral (Vivotif)

First NDA Approval

1998

rabies vaccine adsorbed (BioRab)

Last Known Activity

2022

Timeline

NOW

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Active Ingredients

Marketed Drugs (13)

Key: Emergent BioSolutions (9) Acquired (4)

ANSUVIMAB (Ebanga) (2020 NDA)

anthrax immune globulin (Anthrasil) (2015 NDA)

anthrax vaccine, adsorbed (Biothrax) (1998 NDA)

botulism antitoxin heptavalent (a, b, c, d, e, f, g) - (equine) (BAT) (2013)

brincidofovir (Tembexa) (2021 NDA)

cholera vaccine (Vaxchora) (2016 NDA)

naloxone (narcan) (2015)

rabies vaccine adsorbed (BioRab) (1998 NDA)

raxibacumab (2012)

smallpox vaccine, tissue culture adapted jennerian (ACAM2000) (2007 NDA)

somatropin (protropin) (2008)

typhoid vaccine, live oral (Vivotif) (1989)

vaccinia immunoglobulin (2005)

Drugs in Phase 4 Trials (4)

Key: Emergent BioSolutions (0) Acquired (4)

cholera vaccine (Vaxchora) (6 trials)

hepatitis b immune globulin (human) (BayHep B) (2 trials)

hepatitis b vaccine (recombinant) (Recombivax) (1 trial)

smallpox vaccine, tissue culture adapted jennerian (ACAM2000) (2 trials)

Drugs in Phase 3 Trials (5)

Key: Emergent BioSolutions (2) Acquired (3)

aluminum hydroxide (Gaviscon) (3 trials)

anthrax vaccine, adsorbed (Biothrax) (6 trials)

chikv vlp (3 trials)

coagulation factor ix (Recombinant) (Rixubis) (1 trial)

zanolimumab (5 trials)

Drugs in Phase 2 Trials (16)

Key: Emergent BioSolutions (11) Acquired (5)

anthrax immune globulin (Anthrasil) (2 trials)

Anti-Influenza Immunoglobulin (1 trial)

bendamustine (treanda) (1 trial)

chikungunya vlp (1 trial)

ciprofloxacin (cipro) (2 trials)

cyclophosphamide (cytoxan) (1 trial)

doxorubicin (Doxil) (1 trial)

doxycycline (vibramycin) (1 trial)

immune globulin (human) (Gamastan) (1 trial)

m01zh09 (1 trial)

methylprednisolone (medrol) (1 trial)

otlertuzumab (1 trial)

prednisone (meticorten) (2 trials)

sbi-087 (4 trials)

tru-015 (3 trials)

vincristine (oncovin) (1 trial)

Drugs in Phase 1 Trials (25)

Key: Emergent BioSolutions (13) Acquired (12)

ad4/ad7 vaccine (1 trial)

ad4-envc150 (2 trials)

ad4-h5-vtn (1 trial)

ad4-mgag (2 trials)

ad4-pa-1 (1 trial)

ad4-pa-gpi-1 (1 trial)

aeras-402 (1 trial)

aidsvax b/e (1 trial)

ak1320 (1 trial)

avp-21d9 (1 trial)

botulinum antitoxin heptavalent (a b c d e f g) - (equine) (1 trial)

botulism antitoxin bivalent (equine) types a and b (1 trial)

botulism antitoxin heptavalent (a, b, c, d, e, f, g) - (equine) (BAT) (1 trial)

brincidofovir (Tembexa) (1 trial)

covid 19 immune globulin (1 trial)

covid-higiv (1 trial)

inactivated influenza vaccine (1 trial)

isoamyl nitrite (1 trial)

mva85a (1 trial)

naloxone (narcan) (1 trial)

zika virus immune globulin (1 trial)

Drugs in Other Trials (1)

Key: Emergent BioSolutions (0) Acquired (1)

varicella zoster immune globulin (human) (varizig) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Anthrax (Phase 3)

Arthritis (Phase 3)

Arthritis, Rheumatoid (Phase 3)

Constriction, Pathologic (Phase 1)

Glomerulonephritis, Membranous (Phase 1)

Infections (Phase 1)

Influenza, Human (Phase 2)

Kidney Diseases (Phase 1)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Lupus Erythematosus, Systemic (Phase 1)

Lymphoma (Phase 3)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Lymphoma, T-Cell (Phase 3)

Lymphoma, T-Cell, Cutaneous (Phase 2)

Mycoses (Phase 3)

Mycosis Fungoides (Phase 3)

Sezary Syndrome (Phase 3)

Spinal Stenosis (Phase 1)

Spondylolisthesis (Phase 1)

Syndrome (Phase 3)

Tuberculosis (Phase 1)

Typhoid Fever (Phase 2)

Virus Diseases (Phase 1)

Zika Virus Infection (Phase 1)

Overview

Highest Phase: Phase 3
# of Trials: 61
# of Trial APIs: 51